香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的全部內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：6855） ASCENTAGE PHARMA GROUP INTERNATIONAL 亞盛醫藥集團 自願公告 亞盛醫藥耐立克®一線治療Ph+ ALL的全球註冊III期 臨床研究獲美國FDA和歐洲EMA批准 2024年6月14日，亞盛醫藥與跨國製藥企業武田就奧雷巴替尼簽署了一項獨家選 擇權事宜。一旦行使選擇權，武田將獲得開發及商業化耐立克®的全球權利許可， 惟中國大陸、中國香港特別行政區、中國澳門特別行政區、中國台灣等地區除外。 承董事會命 亞盛醫藥集團 主席兼執行董事 楊大俊博士 值得一提的是，POLARIS-1研究的最新進展也將在即將召開的2025年美國血液 學會（American Society of Hematology，ASH）年會上亮相，這是該研究數據的首 次公佈。目前已披露的摘要數據顯示：在耐立克®聯合低強度化療治療的初治Ph+ ALL患者中， ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 亞盛醫藥集團 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06855 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF ...

Group 1 - The Hong Kong biotechnology sector experienced a widespread decline, with notable drops in several companies' stock prices [1] - Specifically, Gilead Sciences-B fell over 13%, while Sanofi-B dropped more than 10% [1] - Other companies such as Crystal Technology Holdings and Hualing Pharmaceutical-B also saw declines exceeding 6% [1] Group 2 - Gilead Sciences-B's latest price is 11.750, with a market capitalization of 116.56 billion and a year-to-date increase of 290.37% [2] - Sanofi-B's latest price is 7.000, with a market capitalization of 7.44 billion and a year-to-date increase of 102.31% [2] - Crystal Technology Holdings has a latest price of 9.330, a market capitalization of 401.48 billion, and a year-to-date increase of 56.02% [2] - Hualing Pharmaceutical-B's latest price is 3.230, with a market capitalization of 34.13 billion and a year-to-date increase of 121.23% [2] - Other companies like Wangshan Wangshui-B and Sanleaf Biotech-B also reported significant declines, with year-to-date increases of 123.25% and 920.75% respectively [2]

Core Viewpoint - Ascentage Pharma Group International is set to provide an update on its innovative portfolio and pipeline during an investor webcast, focusing on key presentations at the upcoming 67th American Society of Hematology Annual Meeting [1]. Company Overview - Ascentage Pharma is a global, commercial stage, integrated biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapies for unmet medical needs in cancer [4]. - The company has developed a rich pipeline of innovative drug products, including inhibitors targeting key apoptotic pathway proteins and next-generation kinase inhibitors [4]. Product Pipeline - The first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor for treating chronic myeloid leukemia (CML) with specific mutations and is included in the China National Reimbursement Drug List [5]. - The company is conducting a global registrational Phase III trial (POLARIS-2) for Olverembatinib in CML and additional trials for newly diagnosed Ph+ acute lymphoblastic leukemia (ALL) and SDH-deficient gastrointestinal stromal tumors (GIST) [5]. - The second approved product, Lisaftoclax, is a Bcl-2 inhibitor for various hematologic malignancies and is undergoing multiple global registrational Phase III trials [6]. Research and Development - Ascentage Pharma has established a portfolio of global intellectual property rights and formed partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer [7].

证 券 研 究 报 告 行业周报 关注吸入制剂在呼吸疾病领域的突破 医药行业周报 投资评级： 报告日期： 推荐 （ 维持 ） 2025年11月30日 分析师：胡博新 SAC编号：S1050522120002 分析师：吴景欢 SAC编号：S1050523070004 医 药 行 业 观 点 在呼吸疾病领域，如IPF、COPD等，吸入制剂+新靶点组合正取得更多积极的治疗效果。2025年6月10日，Insmed公布其 治疗PAH(肺动脉高压）新药TPIP（曲前列环素棕榈醇吸入粉剂）的临床2b期顶线数据，安慰剂校正的PVR较基线降低35%， LS均值比0.65（p＜0.001）。其冻干粉制剂的设计，不仅实现了用药的方便性，只需每日一次，而且治疗效果也优于曲前 列环素的口服品种。7月9日，默沙东宣布收购一家专注于呼吸系统疾病的生物制药公司Verona Pharma，总交易价值约为 100亿美元。通过此次收购，默沙东将获得一款用于治疗慢性阻塞性肺病（COPD）的重磅新药Ohtuvayre（恩司芬群）， 这是一种针对磷酸二酯酶3和4（PDE3和PDE4）的首创选择性双重抑制剂。FDA于2024年6月批准Ohtuvayre用 ...

Core Viewpoint - The article highlights the development and success of the China Medical City in Taizhou, which has become a significant hub for the biopharmaceutical industry in China, attracting numerous enterprises and fostering innovation in vaccine and medical device research and development [4][5][10]. Group 1: Industry Development - Established in May 2009, the China Medical City is the only national-level high-tech zone in China focused on the pharmaceutical and health industry [5]. - The city has positioned itself as a leader in the biopharmaceutical sector, particularly in vaccine, antibody, and in vitro diagnostic reagent research, differentiating itself from other regions like Shanghai and Suzhou [5][6]. - The city has built the largest vaccine factory center in Jiangsu Province, with over 50 vaccine products in production or research, and has successfully incubated more than 50 enterprises, including 5 listed companies [6][10]. Group 2: Financial Support - In just a few years, the park has nurtured 9 biopharmaceutical companies that have successfully gone public, with 18 more in the pipeline for IPO [7][8]. - The local investment platform, Huayin Financial Investment Co., has invested over 1.2 billion yuan in the park's industries, providing essential financial support to meet the specific needs of biopharmaceutical companies [8][9]. - The financial ecosystem in Taizhou includes various models such as "incubation + angel investment" and "venture capital + insurance," creating a "capital rainforest" that offers tailored financial services to enterprises [9]. Group 3: Comprehensive Services - The China Medical City has developed a complete service chain to support innovation, including preclinical research, clinical trials, and regulatory approval processes, significantly reducing communication costs for enterprises [10][11]. - The establishment of the first drug supervision service complex in China has streamlined the approval process, providing integrated services for drug registration and policy interpretation [11]. - The city has attracted over 50,000 talents, including 4,600 high-level professionals, enhancing its innovation capabilities and supporting the growth of local enterprises [11].

Core Viewpoint - As of the announcement date, the company has granted a total of 1,304,500 restricted stock units (RSUs) to 146 selected individuals under the 2022 Restricted Stock Unit Plan, which corresponds to 1,304,500 shares [1] Summary by Categories Restricted Stock Units - The company has awarded 1,304,500 RSUs to 146 selected individuals under the 2022 plan, with further grants expected in 2022 [1] Stock Options - The company has granted a total of 736,600 stock options to 34 recipients under the post-initial public offering stock option plan, which allows for the subscription of an equivalent number of ordinary shares, pending acceptance by the option recipients [1]

Core Viewpoint - As of the announcement date, the company has granted a total of 1,304,500 restricted stock units to 146 selected individuals under the 2022 Restricted Stock Unit Plan, which corresponds to 1,304,500 shares [1] Group 1 - The company has also granted a total of 736,600 stock options to 34 grantees under the post-IPO stock option plan, which can be exercised to subscribe for a total of 736,600 ordinary shares of the company, pending acceptance by the option grantees [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的全部內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 ASCENTAGE PHARMA GROUP INTERNATIONAL 亞盛醫藥集團 （於開曼群島註冊成立的有限公司） （股份代號：6855） 根據2022年受限制股份單位計劃進一步授出獎勵；及 根據首次公開發售後購股權計劃授出購股權 茲提述(i)亞盛醫藥集團（「本公司」，連同其附屬公司統稱「本集團」）日期為2021 年2月2日、2022年6月23日及2022年7月14日的公告（「該等公告」）；(ii)本公司日 期為2025年4月30日的通函（「該通函」）；及(iii)本公司日期為2025年5月19日的投 票結果公告，內容有關（其中包括）採納2022年受限制股份單位計劃及修訂2022年 受限制股份單位計劃，以及採納首次公開發售後購股權計劃及修訂首次公開發售 後購股權計劃。除另有界定者外，本公告所用詞彙與該等公告及該通函所界定者 具有相同涵義。 根據2022年受限制股份單位計劃進一步授出獎勵 董事會宣 ...

Group 1 - The stock of Ascentage Pharma-B (06855.HK) increased by over 3%, specifically by 3.04%, reaching a price of 64.35 HKD [1] - The trading volume for Ascentage Pharma-B was 46.0484 million HKD at the time of reporting [1]